NEWTOWN SQUARE, Pa., April 12, 2019 /PRNewswire/ -- Kibow Biotech, Inc., Pennsylvania, will feature its product for Kidney Illness, RENADYL™, at the 50th Anniversary Meeting of the American Nephrology Nurse Association (ANNA) in Dallas, Texas, USA. (www.annanurse.org)
RENADYL™, the worlds first and only use of probiotics for those with kidney health issues will be presented to the Nephrology Nurses (i.e., nurses who are kidney health specialists) from across the country, at Hilton Anatole, Dallas, TX 75207, USA, April 12-15, 2019.
Terrence O. Tormey, CEO at Kibow Biotech, said, "Kibow Biotech has been a long-time supporter of this incredible organization! It is a gathering of this nation's finest Nephrology nurses! We recognize that all nurses are important to our healthcare system, and these nurses, like all of them, have a very demanding and difficult job! Additionally, ANNA nurses were among the first in the nation to recognize the importance of the 'gut microbiome,' and its role in a variety of health-related issues, including kidney health." Tormey went on to say that, "We will be discussing how specific strains of probiotics (i.e., beneficial bacteria) can reduce uremic toxins, those which an impaired kidney is not removing."
RENADYL™ is an all-natural, non-GMO, gluten-free, and non-prescription product, which is available online at www.Renadyl.com, on Amazon, and through Fullscript™ throughout the US.
About Kibow Biotech: Founded October 1, 1997, in Philadelphia, Kibow Biotech specializes in research, development, and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and other healthcare applications. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.
The company's extensive scientific (R&D) and clinical data from three different pilot/observational scientific human clinical trials have been published in peer-reviewed scientific /medical journals (http://www.kibowbiotech.com/rd/).
Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA, and the possibility of its approval as a drug in some other countries according to respective governmental authorities.
About Uremic Toxin Reduction Technology – also known as "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/) consists of a combination of three specific probiotic microbial strains and chosen prebiotics.
Kidney health supplement with a pharmaceutical-like validation: Kibow Biotech is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ is not meant to cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors. These include but are not limited to the possibility that Renadyl™ may not reduce levels of uremic toxins in each and every individual, due to differences that exist between individuals that cannot be controlled such as genetics and lifestyle factors, as well as environmental factors that would include proper storage of the product and conditions of transport of the product in the chain of commerce. Other factors that could cause or contribute to differences in actual results include, but are not limited to: whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
For further information, contact:
Terrence O. Tormey – CEO, Kibow Biotech, Inc.
(610) 353-5130 or Email: [email protected]
SOURCE Kibow Biotech, Inc.